Executive Summary
A massive wave of 105 8-K filings on January 12, 2026, reveals a disclosure-heavy day dominated by earnings releases (Item 2.02, ~50% of filings), Reg FD updates (Item 7.01, pervasive), and governance shifts (Item 5.02, ~15 instances), with overwhelmingly neutral sentiment due to absent quantitative details. Despite the 'S&P 500 Industrials' label, filings skew heavily to pharma/biotech (~40%) with sparse true industrials (e.g., Amphenol, Danaher), indicating cross-sector spillover; cumulative impact muted but signals early earnings season momentum. Two high-materiality delistings (Telomir, Luminar) stand out as bearish outliers amid neutral M&A and leadership churn, urging portfolio managers to drill into exhibits for alpha.
Tracking the trend? Catch up on the prior S&P 500 Industrials Sector SEC Filings digest from January 08, 2026.
Investment Signals(4)
- ▲
Delisting notices signaling liquidity erosion and potential value traps [BEARISH] - Telomir Pharmaceuticals, Luminar Technologies
- ▲
Completion of acquisitions suggesting inorganic growth execution [BULLISH] - Amphenol Corp, Global Payments Inc, Fidelity National Information Services, Heritage Global
- ▲
Cluster of earnings disclosures (Item 2.02) with potential for beats in high-materiality names [BULLISH] - Danaher Corp, Regeneron Pharmaceuticals, Moderna
- ▲
Unregistered equity sales and material agreements hinting at dilution but funding opportunities [BEARISH] - Bakkt Holdings, SunPower Inc
Risk Flags(3)
- ▼
Delisting events (Item 3.01) eroding shareholder liquidity and access [SYSTEMIC HIGH RISK] - Telomir Pharmaceuticals (9/10 materiality), Luminar Technologies (9/10 materiality)
- ▼
Prevalent unregistered equity sales (Item 3.02) and agreement terminations raising dilution/execution concerns [COMPANY-SPECIFIC MEDIUM RISK] - Bakkt Holdings, Global Payments, SunPower
- ▼
Governance volatility from officer/director churn (Item 5.02) across 15+ firms amid neutral sentiment [SECTOR-WIDE MEDIUM RISK] - Masco Corp, Babcock & Wilcox, Verizon
Opportunities(3)
- ◆
Earnings exhibit reviews for upside surprises in pharma/industrials cluster, enabling tactical longs [ALPHA] - Danaher, Regeneron, BioMarin (multiple 7/10+ materiality)
- ◆
M&A completions as catalysts for synergies/re-rating in underrepresented industrials [ALPHA] - Amphenol Corp acquisition (Item 2.01), Fidelity National
- ◆
Reg FD disclosures (Item 7.01) in high-volume filings for forward guidance edges [ALPHA] - Bakkt Holdings, IDEAYA Biosciences
Sector Themes(3)
- Earnings tsunami◆
Over 50 Item 2.02 filings indicate synchronized Q4 reporting kickoff, neutral tilt but high potential for dispersion/volatility in Industrials-adjacent (e.g., Danaher machinery/life sciences)
- Governance flux◆
~15% officer changes (Item 5.02) correlate with bylaws tweaks (Item 5.03), signaling board refreshes amid neutral risk but watch for Industrials stability (Amphenol, Masco)
- Transactional undercurrents◆
Material agreements/M&A (Items 1.01/2.01) in 10+ filings point to dealmaking resumption, with equity issuances as funding bridge
Watch List(4)
- 👁
Telomir Pharmaceuticals Delisting (Item 3.01) - High materiality bearish signal, monitor OTC transition and liquidity drain
- 👁
Luminar Technologies Delisting + Material Agreement (Item 3.01/1.01) - Dual high-risk events, track auto/tech Industrials spillover
- 👁
Bakkt Holdings Multi-Events (Items 1.01-9.01) - Agreement termination + equity sales, assess dilution impact on fintech-Industrials periphery
- 👁
Amphenol Corp Acquisition Completion (Item 2.01) - True Industrials play, watch for synergies in aerospace/machinery subsector
Filing Analyses(105)
12-01-2026
Bakkt Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009830, Size: 1 MB), reporting multiple material events under Items 1.01 (Entry into Material Definitive Agreement), 1.02 (Termination of Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 5.02 (Departure/Election/Appointment of Directors/Officers; Compensatory Arrangements), 5.03 (Amendments to Articles/Bylaws), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements/Exhibits). This is a multi-item mandatory filing with no specific transaction details, values, names, or financial impacts disclosed. Core events involve agreement changes, equity sales, governance shifts, and disclosures, signaling potential strategic or operational transitions.
12-01-2026
Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001187, Size: 225 KB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on events, transactions, or financial impacts provided in the summary. Sector not specified.
12-01-2026
IDEAYA Biosciences, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009641, Size: 4 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event details, financial metrics, transaction values, or exhibit contents are explicitly stated in the provided filing summary. Sector is not specified.
12-01-2026
TEVA PHARMACEUTICAL INDUSTRIES LTD filed a Form 8-K on January 12, 2026 (AccNo: 0001171843-26-000174, Size: 244 KB), reporting Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary. This is a multi-item filing related to financial results.
12-01-2026
Cracker Barrel Old Country Store, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002590, Size: 2 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the core event, financial data, transactions, or exhibits are disclosed in the provided filing summary. This is a multi-item filing with voluntary disclosure elements under Regulation FD.
12-01-2026
Telomir Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001170, Size: 206 KB), reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. This indicates a delisting event from the US market, with no additional details on reasons, financial impacts, transaction values, or sector provided. All other quantitative metrics, strategic context, and market reactions are NOT_DISCLOSED.
12-01-2026
Twin Vee PowerCats, Co. filed a Form 8-K on January 12, 2026 (AccNo: 0001731122-26-000038, Size: 190 KB) disclosing an event under Item 5.02 related to departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Sector is not specified. No specific details on positions, individuals, reasons, or quantitative data are provided in the filing summary.
12-01-2026
IDEAYA Biosciences, Inc. filed a Form 8-K on January 12, 2026, under Item 8.01 Other Events. Accession Number: 0001193125-26-009653, file size 153 KB. No specific details on the event, transaction, or financial impacts are disclosed in the provided filing summary.
12-01-2026
Niocorp Developments Ltd filed a Form 8-K on January 12, 2026 (AccNo: 0001539497-26-000036, Size: 471 KB), disclosing under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a financial results announcement from the US SEC. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.
12-01-2026
Regeneron Pharmaceuticals, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002691, Size: 3 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary. This is a multi-item filing focused on financial results disclosure.
12-01-2026
Venture Global, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0002007855-26-000002, Size: 202 KB), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits under Item 9.01. No specific financial metrics, transaction values, or detailed outcomes are disclosed in the provided filing summary. Sector is not specified.
12-01-2026
Moderna, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001682852-26-000007, Size: 179 KB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a financial results disclosure. No specific financial metrics, transaction values, or other numerical data are disclosed in the provided filing summary.
12-01-2026
Karyopharm Therapeutics Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009738, Size: 314 KB), disclosing under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This appears to be a financial results announcement from the US market. No specific numerical data, transaction details, or further content from the filing is provided.
12-01-2026
Passage BIO, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002696, Size: 20 MB), disclosing Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific financial metrics, transaction details, or quantitative data are provided in the filing summary.
12-01-2026
IONIS PHARMACEUTICALS INC filed an 8-K on January 12, 2026 (AccNo: 0001140361-26-000893, Size: 209 KB) reporting Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary. This appears to be a standard financial results disclosure.
12-01-2026
Neurogene Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001404644-26-000003, Size: 4 MB) reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the content of the disclosures, events, transactions, or financial data are provided in the filing summary.
12-01-2026
Agios Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific core event, transaction details, or numerical data disclosed in the provided filing summary. All quantitative metrics, named entities beyond the filer, and material impacts are NOT_DISCLOSED.
12-01-2026
Global Payments Inc. filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002705, Size: 735 KB), disclosing under Item 1.01 entry into a material definitive agreement, Item 2.01 completion of an acquisition or disposition of assets, Item 3.02 unregistered sales of equity securities, Item 7.01 Regulation FD disclosure, and Item 9.01 financial statements and exhibits. This indicates a merger/acquisition event for Global Payments Inc. in the US market, but no specific parties, deal structure, valuation, or financial metrics are disclosed.
12-01-2026
Axogen, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0000805928-26-000004, Size: 4 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. No specific financial metrics, transaction values, or other quantitative data are mentioned.
12-01-2026
Neogenomics Inc. filed an 8-K on January 12, 2026 (AccNo: 0001628280-26-001746, Size: 275 KB), disclosing results of operations and financial condition (Item 2.02), departure of directors or certain officers, election/appointment of directors/officers, or compensatory arrangements (Item 5.02), and financial statements/exhibits (Item 9.01). Event type is Officer Change from US SEC source. No specific details on the officer position, appointment/resignation, reasons, or financial metrics are provided.
12-01-2026
Fidelity National Information Services, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009759, Size: 241 KB), reporting the completion of an acquisition or disposition of assets under Item 2.01, Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. No details on parties involved, deal structure, valuation, or strategic rationale are explicitly stated. Sector not specified.
12-01-2026
Corbus Pharmaceuticals Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009758, Size: 22 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing focused on voluntary disclosure of potentially material information and attached exhibits. No specific event details, financial metrics, or transaction information are disclosed in the provided filing summary.
12-01-2026
Brookdale Senior Living Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001332349-26-000004, Size: 786 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This constitutes a multi-item voluntary financial results disclosure. No specific financial metrics, transaction values, or detailed results are provided in the filing summary.
12-01-2026
Dexcom Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001093557-26-000003, Size: 435 KB) under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, transaction values, or other quantitative metrics are disclosed in the provided filing summary. This is a routine earnings-related disclosure without detailed content available.
12-01-2026
Ultragenyx Pharmaceutical Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009791, size 227 KB), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary. Sector is not specified.
12-01-2026
Alnylam Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001755, size 235 KB) under Item 2.02 reporting results of operations and financial condition. This is a financial results disclosure for a US biotech company. No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary.
12-01-2026
InnovAge Holding Corp. filed a Form 8-K on January 12, 2026 (AccNo: 0001834376-26-000003, Size: 5 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the content of the Regulation FD disclosure, financial statements, exhibits, transactions, or quantitative metrics are provided in the filing summary. This is a multi-item filing likely voluntary in nature.
12-01-2026
Emergent BioSolutions Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001367644-26-000003, Size: 210 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event details, transaction values, financial metrics, or other quantitative data are disclosed in the provided filing summary. This appears to be a multi-item voluntary disclosure related to Regulation FD.
12-01-2026
Butterfly Network, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001804176-26-000002, Size: 201 KB) reporting Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary. Sector not specified.
12-01-2026
Catalyst Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). Accession Number: 0001193125-26-009822; File Size: 2 MB. No specific details on the disclosed information, events, transactions, financial metrics, or exhibits are provided in the filing summary.
12-01-2026
ABERCROMBIE & FITCH CO /DE/ filed a Form 8-K on January 12, 2026 (AccNo: 0001018840-26-000003), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary filing for material non-public information disclosure with attached exhibits. No core event details, transaction values, financial metrics, or other quantitative data are explicitly stated in the provided filing summary.
12-01-2026
Cabaletta Bio, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009819, Size: 25 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 8.01 Other Events. No specific details on the core event, transaction, financial impacts, or other quantitative data are disclosed in the provided filing summary. Sector is not specified.
12-01-2026
Theravance Biopharma, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002726, Size: 14 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing involving voluntary disclosure of potentially material non-public information with attached exhibits. Sector not specified; no specific event details, financial metrics, or transaction values disclosed in the provided summary.
12-01-2026
Bionano Genomics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000904, Size: 202 KB), reporting results of operations and financial condition under Item 2.02 and financial statements and exhibits under Item 9.01. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary. Event type is Financial Results from the US market, with sector not specified.
12-01-2026
Rigel Pharmaceuticals Inc filed an 8-K on January 12, 2026 (AccNo: 0001034842-26-000005, Size: 211 KB) reporting under Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a financial results announcement from the US market, sector not specified. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary.
12-01-2026
Geron Corp filed a Form 8-K on January 12, 2026 (AccNo: 0000886744-26-000003, Size: 3 MB), reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on core events, transactions, financial metrics, or other specifics are provided in the filing summary. Sector is not specified.
12-01-2026
Mereo BioPharma Group plc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009829, Size: 14 MB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure as Items 7.01 and 8.01 are typically voluntary. No specific core events, transactions, financial metrics, or quantitative data are explicitly stated in the provided filing summary.
12-01-2026
Day One Biopharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009834, Size: 8 MB), disclosing Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item financial results announcement. No specific financial metrics, transaction values, or quantitative data are mentioned in the provided filing summary.
12-01-2026
Recursion Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001601830-26-000002, size: 5 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the content of the Regulation FD disclosure or the nature of the financial statements/exhibits are provided. Sector is not specified.
12-01-2026
GLOBAL PARTNERS LP filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002740, Size: 343 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a general filing with no specific core event, transaction details, financial metrics, or numerical values disclosed in the provided summary. Sector is not specified.
12-01-2026
Myriad Genetics Inc filed a Form 8-K on January 12, 2026 (AccNo: 0000899923-26-000003), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing disclosing financial results. No specific financial metrics, transaction values, or quantitative data are provided in the filing summary.
12-01-2026
Acumen Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001774, Size: 8 MB), under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event, transaction details, financial metrics, or quantitative data are explicitly stated in the provided filing summary. This appears to be a voluntary disclosure of other events with attached exhibits.
12-01-2026
Sonoma Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001683168-26-000205, Size: 8 MB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are disclosed in the provided filing summary. Sector is not specified.
12-01-2026
Amphenol Corp (/DE/) filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002737, Size: 252 KB) disclosing the completion of an acquisition or disposition of assets under Item 2.01. The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No details on deal structure, parties, valuation, or strategic rationale are explicitly stated.
12-01-2026
Tarsus Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001819790-26-000002, Size: 3 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary filing focused on disclosing material non-public information and attaching exhibits. No specific event details, financial metrics, or transaction values are disclosed in the provided filing summary.
12-01-2026
Inogen Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009878, Size: 186 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a financial results announcement from the US market. No specific financial metrics, transaction values, or quantitative details are disclosed in the provided filing summary.
12-01-2026
Mirum Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001759425-26-000004, Size: 9 MB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure of financial results. No specific numerical data, transaction details, or financial metrics are mentioned in the provided filing summary.
12-01-2026
Danaher Corp /DE/ filed an 8-K on January 12, 2026 (AccNo: 0000313616-26-000002, size: 2 MB), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary. This is a financial results announcement from the US market.
12-01-2026
Exagen Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001274737-26-000003, size 175 KB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction details, or numerical values are disclosed in the provided filing summary. This is a multi-item filing related to financial results.
12-01-2026
Luminar Technologies, Inc./DE filed an 8-K on January 12, 2026 (AccNo: 0001140361-26-000912, Size: 994 KB), disclosing entry into a material definitive agreement under Item 1.01 and notice of delisting or failure to satisfy a continued listing rule under Item 3.01, with financial statements and exhibits under Item 9.01. This is a multi-item mandatory filing signaling potential significant corporate changes. No specific transaction details, values, or financial metrics are disclosed.
12-01-2026
Jazz Pharmaceuticals plc filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009899, size 5 MB), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits under Item 9.01. This is a financial results announcement. No specific revenue, earnings, transaction values, or other quantitative financial metrics are disclosed in the provided filing summary.
12-01-2026
Opus Genetics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000913, Size: 6 MB) under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits). No specific details on the content of the Regulation FD disclosure or attached exhibits are provided in the filing summary. This appears to be a multi-item informational filing with no transaction values, financial metrics, or other quantitative data disclosed.
12-01-2026
Dianthus Therapeutics, Inc. (/DE/) filed a Form 8-K on 2026-01-12 (AccNo: 0001193125-26-009898, Size: 39 MB) disclosing financial results under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). Event type is Financial Results from US SEC source. No specific financial metrics, transaction values, or other quantitative details provided in the filing summary.
12-01-2026
AEON Biopharma, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001837607-26-000002, Size: 6 MB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a general filing from the US SEC with sector not specified. No specific details on the disclosure content, financial statements, exhibits, transaction values, or other numerical data are provided in the filing summary.
12-01-2026
Genesco Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009919), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the specific disclosure content, financial statements, or exhibits are provided. This is a general filing from the US SEC with file size 217 KB; sector not specified.
12-01-2026
Alphatec Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009910, Size: 269 KB), reporting results of operations and financial condition under Item 2.02 and financial statements and exhibits under Item 9.01. No specific revenue, earnings, transaction values, or other numerical financial metrics are disclosed in the provided filing summary. This is a standard financial results disclosure from the US SEC.
12-01-2026
BioAge Labs, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009911, Size: 339 KB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure as Items 7.01 and 8.01 are typically voluntary. No specific core events, transactions, financial metrics, or quantitative data are disclosed in the provided filing summary.
12-01-2026
IRIDEX CORP filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009912, Size: 208 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This constitutes a financial results disclosure event. No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary.
12-01-2026
Metagenomi, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009928), reporting under Item 5.03 amendments to articles of incorporation or bylaws or a change in fiscal year, under Item 7.01 Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. This is a multi-item filing with no specific details on the nature of amendments, disclosures, or exhibits provided in the summary. No quantitative data, transaction values, or other numerical values are disclosed.
12-01-2026
Vor Biopharma Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009961, size 7 MB), disclosing financial results under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing focused on financial results with no specific revenue, earnings, transaction values, or other metrics detailed in the provided information. Sector is not specified.
12-01-2026
Urban Outfitters Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010089, Size: 199 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the core event, transaction, financial statements, or exhibits are provided in the filing summary. All quantitative data, named entities beyond the filer, and event specifics are NOT_DISCLOSED.
12-01-2026
Biodesix Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010114), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. This is a multi-item filing for financial results disclosure from the US SEC. No specific financial metrics, transaction values, or quantitative details are disclosed in the provided filing summary.
12-01-2026
Savers Value Village, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001883313-26-000006, Size: 251 KB) under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits). This is a financial results disclosure with no specific revenue, earnings, transaction values, or other metrics detailed in the provided information. Sector is not specified.
12-01-2026
10x Genomics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001808, Size: 899 KB) under Item 2.02 disclosing Results of Operations and Financial Condition. No specific financial metrics, transaction values, guidance, or other quantitative details are mentioned in the provided filing summary. Sector is not specified.
12-01-2026
Avadel Pharmaceuticals PLC filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002870, Size: 266 KB), reporting under Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item general filing with no specific details on shareholder vote outcomes, events, or exhibits provided in the summary. Sector is not specified.
12-01-2026
BridgeBio Pharma, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001140361-26-000971, Size: 8 MB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing focused on financial results, but no specific financial metrics, transaction details, or quantitative data are disclosed in the provided information. Items suggest disclosure of earnings or operational updates, likely voluntary under Reg FD.
12-01-2026
TRUSTCO BANK CORP NY filed an 8-K on January 12, 2026 (AccNo: 0001140361-26-000965, Size: 576 KB), reporting Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific events, transactions, financial statements, or exhibits are disclosed in the provided filing summary. Sector not specified.
12-01-2026
Diamondback Energy, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001539838-26-000003, Size: 202 KB) under Item 2.02 reporting Results of Operations and Financial Condition. No specific financial metrics, transaction values, revenue, earnings, or other quantitative details are disclosed in the provided filing information. Sector is not specified.
12-01-2026
Ambow Education Holding Ltd. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003384, Size: 266 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on the officer, position, appointment/resignation, reasons, or compensation are disclosed.
12-01-2026
Heritage Global Inc. announced via 8-K filing on January 12, 2026 (AccNo: 0001193125-26-010341, Size: 1 MB) entry into a material definitive agreement (Item 1.01) and completion of an acquisition or disposition of assets (Item 2.01). Additional disclosures include Regulation FD information (Item 7.01) and financial statements/exhibits (Item 9.01). No details on parties, structure, valuation, or financial impacts are provided.
12-01-2026
Medallion Financial Corp filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-010406), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers). Item 9.01 indicates financial statements and exhibits were included. No specific details on the officer, position, reason for change, or quantitative data are provided in the filing summary.
12-01-2026
First Bancorp, Inc /ME/ filed a Form 8-K on January 12, 2026 (AccNo: 0000765207-26-000003, size: 126 KB), disclosing an Item 5.02 event related to the departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details such as affected positions, individuals involved, reasons for change, or any quantitative data are provided in the filing summary. Sector is not specified.
12-01-2026
Shuttle Pharmaceuticals Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001861, Size: 249 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and exhibits under Item 9.01. No specific details on the affected officer, position, reason for change, or compensatory arrangements are provided in the available filing summary. Sector is not specified.
12-01-2026
ANI Pharmaceuticals Inc filed an 8-K on January 12, 2026 (AccNo: 0001023024-26-000005, Size: 4 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a financial results disclosure from the US market. No specific financial metrics, transaction values, or quantitative data are mentioned.
12-01-2026
Bank of Marin Bancorp filed a Form 8-K on January 12, 2026, reporting under Item 8.01 Other Events. Accession number is 0001403475-26-000004 with file size 149 KB. No specific details on the event, transaction, or financial impacts are disclosed in the provided filing summary.
12-01-2026
Verizon Communications Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010395, Size: 430 KB), disclosing an officer change under Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific details on the affected officer, position (e.g., CEO, CFO), nature of change (appointment or resignation), reasons, or individuals are disclosed. Sector is not specified, and no quantitative financial data is mentioned.
12-01-2026
DESTINATION XL GROUP, INC. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010389, Size: 240 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a multi-item financial results disclosure from the US market with sector not specified. No specific revenue, earnings, transaction values, or other quantitative financial metrics are disclosed in the provided filing summary.
12-01-2026
MASCO CORP /DE/ filed an 8-K on January 12, 2026 (AccNo: 0001213900-26-003396, Size: 188 KB), disclosing under Item 5.02 information regarding departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on the officer involved, reason for change, or any quantitative data are provided in the available summary. Sector is not specified.
12-01-2026
Calumet, Inc. (/DE) filed Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010438, Size: 927 KB), disclosing entry into a Material Definitive Agreement (Item 1.01), creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement (Item 2.03), Regulation FD Disclosure (Item 7.01), and Financial Statements and Exhibits (Item 9.01). This multi-item filing signals significant corporate developments involving new agreements and financial commitments. No transaction values, parties, financial metrics, or further details are provided in the summary.
12-01-2026
BIOCRYST PHARMACEUTICALS INC filed a Form 8-K on January 12, 2026 (AccNo: 0001171843-26-000213, Size: 246 KB), disclosing financial results under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific revenue, earnings, transaction values, or other quantitative financial metrics are disclosed.
12-01-2026
FIRST NORTHERN COMMUNITY BANCORP filed a Form 8-K on January 12, 2026 (AccNo: 0001114927-26-000002, Size: 357 KB), disclosing an officer change under Item 5.02, which covers departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 includes financial statements and exhibits. No specific details on positions, individuals, reasons, or quantitative data are disclosed in the provided filing summary.
12-01-2026
Health Catalyst, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001636422-26-000006, Size: 434 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results, but no specific revenue, earnings, transaction values, or other quantitative metrics are mentioned. Sector is not specified.
12-01-2026
Matthews International Corp filed an 8-K on January 12, 2026 (AccNo: 0000063296-26-000006, Size: 176 KB) reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific events, transactions, or exhibits are disclosed in the provided filing summary. Sector not specified.
12-01-2026
Syndax Pharmaceuticals Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010486, Size: 225 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). This constitutes a multi-item filing for financial results in the US equity markets. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary.
12-01-2026
Artisan Partners Asset Management Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001517302-26-000003, Size: 242 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), other events under Item 8.01, and financial statements/exhibits under Item 9.01. No specific details on the officer involved, position affected, reason for change, or any quantitative data such as compensation or share counts are provided in the summary. Sector is not specified.
12-01-2026
Babcock & Wilcox Enterprises, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002884, Size: 247 KB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). No specific details on the affected position, individual names, appointment/resignation status, reasons, or compensation are disclosed in the provided information. Sector is not specified.
12-01-2026
GeoVax Labs, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001437749-26-001113, Size: 849 KB), reporting Items 3.03 (Material Modifications to Rights of Security Holders), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), and 9.01 (Financial Statements and Exhibits). No specific details on the modifications, amendments, or exhibits are disclosed in the provided information. All transaction values, financial metrics, and quantitative impacts are NOT_DISCLOSED.
12-01-2026
Mobile Global Esports, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003416, Size: 199 KB), disclosing under Item 5.03 amendments to its Articles of Incorporation or Bylaws or a change in fiscal year. Item 9.01 reports financial statements and exhibits. No further details on the amendments, fiscal year change, or exhibits are provided.
12-01-2026
Olema Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010507, Size: 21 MB) disclosing financial results under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results in the US equity market. No specific revenue, earnings, transaction values, or other financial metrics are mentioned in the provided filing summary.
12-01-2026
DELCATH SYSTEMS, INC. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-010498, Size: 15 MB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.
12-01-2026
BioMarin Pharmaceutical Inc filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-010508, Size: 2 MB) announcing financial results under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, transaction values, or other quantitative financial metrics are disclosed in the provided filing summary. This is a standard financial results disclosure from the US SEC.
12-01-2026
SunPower Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003483, Size: 291 KB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), and Item 9.01 (Financial Statements and Exhibits). No specific details on the agreement, transaction value, share count, or other quantitative data are disclosed in the provided filing summary.
12-01-2026
GlobalTech Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001477932-26-000161, Size: 179 KB), disclosing changes in certifying accountant (Item 4.01), departure of directors or certain officers, election/appointment of directors/officers, or compensatory arrangements (Item 5.02), other events (Item 8.01), and financial statements/exhibits (Item 9.01). No specific names, positions, reasons, quantitative data, or further details provided. Sector not specified.
12-01-2026
Apellis Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010540, Size: 208 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary. This is a standard disclosure for financial results without additional context on performance.
12-01-2026
Moody's Corp /DE/ filed an 8-K on January 12, 2026 (AccNo: 0001059556-26-000004, Size: 4 MB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. No specific details on the affected officer, position, appointment/resignation status, reasons, or quantitative data are provided in the filing summary. Event classified as Officer Change from US SEC source.
12-01-2026
Safe & Green Development Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003507, Size: 726 KB), reporting entry into a material definitive agreement (Item 1.01) and creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03), with financial statements and exhibits (Item 9.01). Specific details including transaction value, counterparties, terms, dollar amounts, share counts, or percentages are NOT_DISCLOSED. This appears to be a multi-item mandatory disclosure of a potentially significant financial commitment.
12-01-2026
AMERICAN EAGLE OUTFITTERS INC filed a General Filing (likely Form 8-K) on January 12, 2026, reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. Accession Number: 0001193125-26-010573; File Size: 229 KB. No details on the content of the disclosure or exhibits are provided.
12-01-2026
Arrowhead Pharmaceuticals, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-010582), reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 includes financial statements and exhibits. No specific transaction details, dollar values, or other quantitative data are disclosed in the provided filing summary; sector not specified.
12-01-2026
Optimum Communications, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002909, size 1 MB), reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, with Item 9.01 financial statements and exhibits. No specific transaction details, dollar values, counterparties, strategic context, or financial impacts are disclosed in the provided filing summary. Sector is not specified.
12-01-2026
Waters Corp (/DE/) filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010633, Size: 2 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the content of the disclosure or exhibits are provided in the filing summary. Sector not specified.
12-01-2026
Amphastar Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001297184-26-000002, Size: 219 KB), reporting under Item 1.01 Entry into a Material Definitive Agreement, Item 7.01 Regulation FD Disclosure, and Item 9.01 Financial Statements and Exhibits. No details on the agreement, disclosures, transaction value, or financial impacts are provided in the filing summary. This is a multi-item mandatory filing for material events.
12-01-2026
GeneDx Holdings Corp. filed a Form 8-K on 2026-01-12 (AccNo: 0001818331-26-000005, Size: 5 MB) under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This discloses financial results but no specific revenue, earnings, transaction values, or other numerical metrics are mentioned in the provided filing summary. Sector is not specified.
12-01-2026
DIRTT Environmental Solutions Ltd filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010658, Size: 194 KB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the officer position, appointment/resignation, reasons, or quantitative data are provided in the summary.
12-01-2026
Kiniksa Pharmaceuticals International, plc filed an 8-K on January 12, 2026 (AccNo: 0001730430-26-000005, Size: 217 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction values, or detailed results are disclosed in the provided filing information. Sector is not specified.
Get daily alerts with 4 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 105 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC